Key Highlights

  • Liminatus Pharma's proposed Reverse merger with oncology cell-therapy company InnocsAI, first announced in May 2026, remains pending and was amended once via a revised agreement in July.
  • The company disclosed on August 13, 2026 that it had transferred its listing to the Nasdaq Capital Market and secured an extension of time to regain minimum bid-price compliance.
  • A shareholder-approved Reverse Stock Split was announced August 18, 2026, aimed at helping the company regain compliance with Nasdaq's minimum bid price requirement.
  • The company priced a roughly $4 million stock-and-warrant financing, typical of how development-stage biotechs fund near-term operations.

Liminatus Pharma, Inc. (NASDAQ:LIMN), a clinical-stage biotech, is working through a pivotal stretch involving a proposed merger with oncology cell-therapy company InnocsAI and steps to maintain its Nasdaq listing.

The company's proposed merger with InnocsAI, a private oncology cell-therapy company, was first announced in May 2026 and subsequently amended via a revised definitive merger agreement around early July 2026 to expand the combined company's cancer-focused cell therapy pipeline.

Alongside the pending merger, Liminatus has taken several corporate actions this month, transferring its listing to the Nasdaq Capital Market, securing a compliance extension, and completing a shareholder-approved reverse stock split.

The InnocsAI Merger

Liminatus Pharma's proposed merger with InnocsAI represents the company's central strategic pivot. The deal, still pending as of this writing, would combine Liminatus with a private oncology cell-therapy company, with the goal of expanding the combined entity's cancer-focused cell therapy pipeline.

Reverse mergers of this kind are common paths for private biotech Assets to access public markets. A successful close would bring InnocsAI's cell-therapy programs into the public markets under the Liminatus corporate structure.

Nasdaq Listing Steps

On August 13, 2026, the company disclosed that it had transferred its listing to the Nasdaq Capital Market and secured an extension of time to regain compliance with the exchange's minimum bid price requirement. Days later, on August 18, 2026, Liminatus Pharma announced a reverse stock split of its common stock, following Shareholder approval, a move explicitly aimed at helping the company regain that compliance.

These steps reflect a company actively managing its listing status while simultaneously advancing its most significant corporate transaction.

Financial Position

Liminatus Pharma is a small, pre-commercial biotech, and companies at this stage typically operate with limited cash reserves, no meaningful product revenue, and recurring net losses funded through Equity and Warrant issuances. Consistent with that profile, the company recently priced a roughly $4 million stock-and-warrant financing, a modest capital raise typical of how development-stage biotechs fund near-term operations.

Detailed, audited figures on cash runway, quarterly burn rate, and net loss were not independently verified for this article, and investors should consult Liminatus Pharma's most recent SEC filings, including its Quarterly Report and the merger-related proxy materials, for authoritative financial detail.

The Path Forward

The InnocsAI merger closing and the combined entity successfully advancing a CAR-T or broader cell-therapy oncology pipeline represents the company's primary path to creating value that the market recognizes beyond its current pre-merger structure.

Investors following the story should recognize that the deal is not yet closed, the company has already needed a Nasdaq extension and a reverse split just to remain listed, and closing conditions, regulatory review, or shareholder approval could still alter or delay the transaction.

What Comes Next

Investors tracking Liminatus Pharma should watch for confirmation that the reverse split has stabilized the share price above Nasdaq's minimum bid threshold over a sustained period, along with any further Nasdaq staff determinations on listing status. The progress and eventual closing of the InnocsAI merger, including any updated timeline, regulatory clearances, or shareholder votes, is the single largest near-term catalyst.

Investors should also monitor the company's cash position and whether additional financings are announced, and its next quarterly SEC filing for updated financial detail.

A Pending Transformation Alongside Listing Requirements

Liminatus Pharma is navigating simultaneous listing compliance work, a pending transformative merger, and the financing needs typical of a pre-revenue drug developer.

The InnocsAI merger's outcome and Nasdaq compliance status will likely determine the company's near-term trajectory as it works through this pivotal period.